Bioscrip Infusion Services (InfuScience, Inc.), Chantilly, VA

Is Bioscrip Infusion Services (InfuScience, Inc.) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Bioscrip Infusion Services (InfuScience, Inc.) hold a Virginia pharmacy license?

State pharmacy license records for Virginia are not checked: the Department of Health Professions’ license lookup is an interactive search form, which this index does not use. This index reads only that state’s board actions.

Has Bioscrip Infusion Services (InfuScience, Inc.) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Dec 21, 2020) for Bioscrip Infusion Services (InfuScience, Inc.). State board actions: no Virginia Board of Pharmacy action under this exact name and city was found in the Virginia Department of Health Professions’ list of Board of Pharmacy case decisions from the last 90 days (actions dated Aug 17, 2026 to Nov 15, 2026) on Nov 15, 2026.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
InfuScience, Inc.; Bioscrip Infusion Services
Location
Chantilly, VA
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
2
Warning letters on FDA’s actions page
1
Latest action on that page
Oct 8, 2021
FDA Data Dashboard inspections
1 inspection: 1 OAI; 2 published Form 483s
Form 483 text on this page
2 Form 483s, 12 observations
State board records
Not checked (license records); board actions matched: 0

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as InfuScience, Inc., (dba Bioscrip Infusion Services), a 503A facility, with 3 dated actions.

Document
Oct 8, 2021Form 483483 Issued 10/08/2021FDA copy (archived)
Dec 21, 2020Warning letterWarning Letter (12/21/2020)FDA copy (archived)
Jul 30, 2019Form 483483 Issued 07/30/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists InfuScience, Inc., Chantilly, VA (FEI number 3013352224), matched to this page by exact name, city and state. It lists 1 inspection: 1 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Oct 8, 2021Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30133522241154338

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 12 numbered observations in all, across 2 inspections ending Jul 30, 2019 to Oct 8, 2021. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection dated Oct 8, 2021 by FDA (dates on the form not read): 4 observations

Firm on the cover
DDRESS, 4151 Lafaye tte C en ter D r S te 6 00 Inf uScience , Inc. dba Bioscrip I nfusion Services
FEI number
3013352224
Establishment type on the cover
Produ c e r of S t e rile D rug P roducts CI TY, STA TE, ZIP CCOE, COUN TRY Chant i l l y, VA 2 015 1- 1230
FDA district office on the cover
Owings Mills, MD 21117 (
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

The ISO 5 classified aseptic processing areas had particle-generating and visibly dirty equipment or surface.

Specifically, on September 27, 2021, and October 4, 2021, we observed white spots on the HEPA diffuser screens

of all < Redacted B4> laminar air flow hoods i n the buffer room. The ISO 5 classified hoods supp ly <Red acted B

4> HEPA a irflow through the respective HEPA diffuser screens.

The white spots were not removed before or in between aseptic processing of all products produced in those

hoods, such as Rx <Redacted B6> "TPN 3:11460 mlIV 15 Hours 6/week", Rx" <Redacted B6> <Redacted B4> <Redacted B4> mg / <Redacted B4>ml NS Wk 0,2,6, then Q8wk", and Rx <Redacted B6> "DAPTOmycin 770mg in NS <Redacted B4>ml Q24H EP".

Observation 2

Personnel conducted aseptic manipulations in an area that blocked the movement of first pass air around an open unit, either before or after it was filled with sterile product.

Specifically, we observed purportedly sterile connections being made, in order to setup the ACD or replace empty product vials, in front of other component materials. For example, on September 27, 2021, the component product "<R edacted B4>" tubing connection was made in front of mounted vials containing <Redac te d

B4> and < Redacted B4>, blocking fist pass air. Similarly, on September 29, 2021, the component p roduct <Redacted B4> was made in front of mounted vials c ontainin g <Redac ted B4> and <Redacted B4>.

Furthermore, your smoke studies do not provide assurance that first pass air is maintained for purportedly sterile connections made in front of other component materials.

Observation 3

IS0-5 classified areas were not certified under dynamic conditions.

Specifically, unidirectional airflow was not verified under dynamic operational conditions representative of your aseptic processing practices. Air visualization studies ("smoke studies") performed in your ISO 5 classified

laminar airflow hoods, <Redacte d B4> of which (H oods <Red acted B4> are designated for total parenteral nutrit

ion (TPN) preparations, did not demonstrate unidirectional airflow, for example, around hanging IV bags, and component materials such as vials and syringes mounted on the metal ra ck of th e <Redacted B4> automatic compounding device (ACD). The metal rack consists of a pproximately <Redacted B4> poles and additionally

, bags are hung on the bar within the hood. Your standard configuration setup fo r this ACD contains <Re

dacted B4> component product port connections, approximately <Redacted B4> of which are mounted to the met

al poles. The smoke studies conducted in August 2021 were conducted with tubing connections made to one v ial, one IV bag, and manipulation on the hood deck with one syringe. The ACD, including the metal rack, o ccu ...

Read the full 483 (PDF on fda.gov)

Observation 4

Media fills were not performed that closely simulate aseptic production operations incorporating, as

appropriate, worst-case activities and conditions that provide a challenge to aseptic operations.

Specifically,

A. Your facility's media fil ls do not represent the quantity and type of connections used to produce total parenteral nutrition (TPN) drug products using the <R edacted B4> automatic compounding device (ACD) a s observed during production.

B . Your facility does not incorporate positive and negative controls to demonstrate growth promotion within your media fil ls.

Inspection Jul 23, 2019 to Jul 30, 2019: 8 observations

Firm on the cover
InfuScience, Inc. dba Biosc rip Infusion Services, 4151 Lafayette Center Dr., Suite 600, Chanttilly, VA 20151-1220
FEI number
3013352224
Establishment type on the cover
Producer of sterile drug products
FDA district office on the cover
6000 Metro Drive, Suite 101 Bal timore, MD 21215
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

You produced beta.-lactam drugs without providing adequate segregation, cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.

Specifically,

A. On July 25, 2019, a portion of"Meropenem 1 g/ 50 ml NS IVP Q8H" (Rx <Redacted B4>) spouted out of the syringe onto the working surface of the ISO 5 classified area of laminar flow hood 1 during production. Upon completion of producing the product, cleaning was performed by wiping the exposed working surface of the laminar flow hood with a sterile wipe and sterile <Redacted B4>. Following, two additional beta-lactam products were produced with subsequent cleaning of the exposed working surface of the laminar flow hood with a sterile wipe and sterile <Redacted B4> Immediately after, a non-beta-lactam product, "0.9% NaCL 500 ml IV daily via HP" (Rx <Redacted B4> was produced without cleaning to prevent cross-contamination from a beta-lactam product. Rx <Redacted B4> !was released and distributed.

B. ...

Read the full 483 (PDF on fda.gov)

Observation 2

The ISO 5 classified aseptic processing areas had visibly dirty equipment or surface.

Specifically, on July 23 -26, 2019, the rear HEPA filter <Redacted B4> laminar air flow hoods~ were observed with white "staining." The <Redacted B4> supplies the ISO 5 classified production area with <Redacted B4> HEP A airflow. The «staining'' was not removed before or in between aseptic processing of all products produced in those hoods, such as "TPN 3-in-l 4000 mL, over 13 hours," (Rx <Redacted B4> Management stated that all total parenteral nutrition (TPN) products are produced in those~ hoods.

Observation 3

Personnel conducted aseptic manipulations and placed equipment/supplies in an area that blocked the movement of first pass air around an open unit, either before or after it was filled with sterile product.

Specifically,

A. On July 25, 2019, during sterile production of."TPN 3-in-1 1055mL IV over 8 hrs" ~ <Redacted B4> in hood ~a technician manipulated sterile connections between an IV lipid bag and the( <Redacted B4> compounder such that IV bags hanging in the ISO 5 classified area blocked the exposed sterile connection from first pass air.

B. On JulY, 26( 2019, during sterile production of "TPN 3-in-1 4000 mL, over 13 hours," (Rx <Redacted B4>, 1 in hood another technician manipulated sterile connections between <Redacted B4> "IV bag and the <Redacted B4> compounder in front of the <Redacted B4> equipment such that the exposed sterile connection was blocked from first pass air in the ISO 5 classified area.

Observation 4

Personnel did not disinfect and change gloves frequently enough to prevent contamination.

Specifically,

A. On July 23, 2019, a technician reached with a gloved hand and forearm into a trash receptacle in the ISO 7 classified "IV Compounding Room" to push down trash and returned to aseptic processing of "TPN 3-in-I 1800 mL, over 12 hours, QD" (Rx <Redacted B4> I) in the ISO 5 classified laminar flow hood without changing or sanitizing gloves and coveralls.

On July 23, 2019, a technician reached with a gloved hand and forearm into a trash receptacle in the ISO 7 classified "IV Compounding Room" to push down trash and returned to aseptic processing of "TPN 3-in-I 1800 mL, over 12 hours, QD" (Rx <Redacted B4> I) in the ISO 5 classified laminar flow hood without changing or sanitizing gloves and coveralls.

B. On July 23, 2019, technicians repeatedly reached back and forth between the ISO 7 classified "N Compounding Room" and the ISO 5 classified laminar flow hoods, such as to obtain materials from their respective stock carts and to use a <Redacted B4> without changing or sanitizing gloves. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Materials or supplies were not disinfected prior to entering the aseptic processing areas.

Specifically, on July 23, 2019, technicians brought materials such as product vials, syringe pouches, and lV bags from the ISO 7 classified "IV Compounding Room" into the ISO 5 classified laminar flow hoods without disinfecting the outer surfaces. Transfers of materials without being disinfecting were observed during production 1of"Cefazolin 2 g/ 20ml in Sterile Water syringe " (Rx <Redacted B4> pin ho > 'fN 3-in-k,L7?0 mL IV 12 Hours" (Rx <Redacted B4> in hood and "TPN 3-in-1 2100 m.L" (Rx.[(15H6) ) in hood <Redacted B4> <>

Observation 6

Disinfectant contact time (also known as "dwell time") and coverage of the item being disinfected were insufficient to achieve adequate levels of disinfection.

Specifically,

S."l.:;;:. C'"l· 3:::, • \C. A . 07-30-19 during <Redacted B4> cleaning <Redacted B4> production operations, the use of disinfectant Solution" sterile germicidal disinfectant in the ISO 5 classified laminar flow hoods( <Redacted B4> did not dwell to achieve your required contact time of <Redacted B4>. Some areas of the hood had a syringe time of less than five seconds.

~-~ ~ 0'1- - °!>• - \<\ B.On 07-30-19, upon usage of your disinfectant, sterile <Redacted B4> on exposed working surfaces of ISO 5 classified laminar flow hoods in between production of different products, your required contact time for bactericidal activity of <Redacted B4> was not achieved. Cleaning of some hoods had a sterile <Redacted B4> drying time of Jess than five seconds.

required contact time for bactericidal activity of (b) ( 4) I was not achieved. Cleaning of some hoods had a sterile.(b) ( 4) I drying time of Jess than five seconds.

•.:,(l~ 0'"1 · 10 C. ...

Read the full 483 (PDF on fda.gov)

Observation 7

ISO 5 classified areas were. not certified under dynamic conditions.

Specifically, unidirectional airflow was not verified under dynamic operational conditions representative of your aseptic processing practices. Smoke studies performed in the <Redacted B4> ISO 5 classified laminar flow hoods did not demonstrate unidirectional airflow, for example, around IV bags hung in each hood and the presence of a repeater or <Redacted B4> pump.

Observation 8

The facility design was observed to allow the influx of poor quality air into a higher classified area.

Specifically, there are: <Redacted B4> locate <Redacted B4> the unclassified before general pharmacy area and. the ISO 7 classified "IV Compounding Room." All production materials are exchanged <Redacted B4> permitting unclassified air to enter the ISO 7 classified area.

State board of pharmacy records

State pharmacy license records for Virginia are not checked: the Department of Health Professions’ license lookup is an interactive search form, which this index does not use. This index reads only that state’s board actions. Board actions source.

What this covers: Board of Pharmacy case decisions the Department of Health Professions lists as entered in the last 90 days, worded as it gives them. Older decisions are reachable only through a search form, which this index does not use, so only that 90-day window is checked. The orders themselves sit behind a disclaimer form and are not linked. Virginia pharmacy licenses are not checked. Actions in the data are dated Aug 17, 2026 to Nov 15, 2026.

Same name at other locations

FDA lists these records under the same name at another location. A shared name does not establish that they are the same firm.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.